Page 1 of **2**′ 3 Form PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY, DOCKET NO. SERIAL NO. (MODIFIED) PATENT AND TRADEMARK OFFICE 080382-0108 09/899,526 APPLICANT INFORMATION DISCLOSURE CITATION Royce Morrison October 29, 2001 NCT 2 9 2001 **FILING DATE GROUP ART UNIT** 3623 07/06/01 (Use several sheets if neces TENT DOCUMENTS **FILING DATE EXAMINER DOCUMENT** SUB-DATE NAME CLASS REF IF INITIAL CLASS NUMBER APPROPRIATE PC Α1 5,862,223 01/19/1999 Walker et al. 5,867,821 02/02/1999 Ballantyne et al. D ( **A2** DeBruin-Ashton 6,014,629 01/11/2000 P( **A3** 10/12/1999 5,964,700 Tallman et al. PC Α4 6,012,035 01/04/2000 Freeman Jr. et al. **A5** 11/09/1999 Schmitt 5,983,220 **A6** 01/25/2000 Herbert III 6,018,742 **A7** FOREIGN PATENT DOCUMENTS TRANSLATION **DOCUMENT** SUB-DATE COUNTRY **CLASS** REF NUMBER **CLASS** YES NO PC 0 957 201 05/13/1998 **EPO 8A** 07/06/2000 PC **WIPO** WO 00/39737 **A9** OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Drug Approvals Part 1 (A-C), 9 pp., http://www.fda.gov/cder/approval/main.htm (printed November 2000). A10 PC Hradecky, G., "Blotechnology: 21st century medicine, Biotech expands its role in the world of medical A11 innovation," Pharmaceutical Representative, pp. 18-19, January 2000. Sackett, D. L. et al., Evidence-based Medicine, How to Practice and Teach EBM, pp. 1-20., Churchill A12 Livingstone, ed., 1997. Gabe, L. et al., "Breaking through the access barrier," Pharmaceutical Representative, p 23., October 1999. A13 PC "Report addresses physician access," Pharmaceutical Representative, p.13, February 2000. A14 **DATE CONSIDERED EXAMINER** 

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Page 2 of 3 Form PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO. SERIAL NO. (MODIFIED) PATENT AND TRADEMAR 080382-0108 09/899,526 **APPLICANT** INFORMATION DISCLOSURE CITATION Royce Morrison OCT 2 9 2001. October 29, 2001 **FILING DATE GROUP ART UNIT** 2161 3623 (Use several sheets if neckary) 07/06/01 OTHER DOCUMENTS (Fiblinding Author, Title, Date, Pertinent Pages, Etc.) Page, L., "More clinics ban drug samples, citing cost, safety concerns," American Medical News, 4 pp, PC A15 October 16, 2000. recnno! 品 "Headache treatments lag behind," Pharmaceutical Representative, p. 16, May 2000. A16 Elliott, V. S., "Hypertension remains poorly controlled," American Medical News, 2 pp., Septemb 21, 200 A17 Weber, J. et al., "The New Era of Lifestyle Drugs," Business Week, pp. 92-98, May 11, 1998. A18 Stevens, L., "Information at the point of patient contact," Medicine on the Net, pp. 5-6, June 2000, A19 http://www.corhealth.com. Foubister, V., "Physicians rarely give patients enough information," American Medical News, p. 15, January 17, A20 2000. "DTC ads 'have created Rx awareness levels similar to those of OT brands," Marketletter via news Edge A21 Corporation, pp. 1-4, March 22, 1999. A22 Promotional Material from Novartis Pharmaceuticals Corporation regarding Lamisil®, 5 pp., 1998. Kolata, G., "Pharmacists Help Drug Promotions," The New York Times, pp. A1, D2, July 29, 1994. **A23** O'Harrow, R., "Plans' Access To Pharmacy Data Raises Privacy Issue," The Washington Post, pp. A1, A26, A24 A27, September 27, 1998. O'Harrow, R., "Between Doctor and Patient, a Three-Way Relationship," The Washington Post, p. A26. A25 September 27, 1998. Hilzenrath, D., "Drug Firms Said to Pressure Doctors," The Washington Post, p. E3, August 14, 1997. A26 McCarthy, R., "Linking Physicians, Pharmacists, and PBMs Electronically," Drug Benefit Trends, Vol. 9(10), pp. A27 36-39, October 1997. Pomerantz, J., "A Case of Inappropriate Use of Patient Pharmacy Data," Drug Benefit Trends, Vol. 12(1), pp. A28 2,6, January 2000. **EXAMINER** DATE CONSIDERED EXAMINER: Initial if citation c nsidered, whether or not citation is in conformance with MPEP 609; Draw line thr ugh citati n if not in c nf rmance and n t consid red. Include any copy of this form with next communication to applicant.

Page 3 of 3

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE		ATTY. DOCKET NO.	SERIAL NO.
(MODIFIED)		PATENT AND TRADEMARK OFFICE		080382-0108	09/899,526
APPLICANT					
INFORMATION DISCLOSURE CITATION (				Royce Morrison	
		October 29, 2001	OCT 2 9 2001	FILING DATE	GROUP ART UNIT
ľ	(Use s	everal sheets if neces	segy)	07/06/01	3623
OTHER DOCUMENTS Publing Author, Title, Date, Pertinent Pages, Etc.)					
ρC	A29	Lo B. et al, "uses and Abuses of Prescription Drug Information in Pharmacy Benefits Management Programs," <u>Journal of American Medical Association</u> , Vol. 283, pp. 801-806, 2000.			
PC	A30	Rosoff, A., "The Changing Face of Pharmacy Benefits Management: Information Technology Pursues a Grand Mission, "Saint Louis University Law Journal, Vol. 42(1), pp. 1-53, 1998.			
PC	A31	L. Caba, "A Life-Saving Preceptorship," Pharmaceutical Representative, pg. 16, July 1998.			
PC	A32	Stevens, L., "Evidence-based Medicine: Applying New Rules to Medical Problem Solving," Medicine on the Net, May 1998, http://www.mednet-i.com.			
PC	A33	Wechsler, J., "A Conversation With FDA Commissioner Jane Henney," Pharmaceutical Executive, pp. 32-36, 38, 40, 42, December 1999.			
PL	A34	Fleming, M., "Cheers and Concerns For DTC From A Family Physician," MM&M, pp. 74, 76, 78, November 1998.			
PC	A35	S. G. Stolberg, "Now, Prescribing Just What the Doctor Ordered," New York Times, pg. 3, section 4, August 10, 1997.			
PC	A36	Mulrow, C., "Systematic Reviews: Critical Links in the Great Chain of Evidence, <u>Annals of Internal Medicine</u> , Vol. 126, No. 5, pp. 389-391, March 1, 1997.			
PC	A37	"Ensuring Quality Health Care: The Challenge of Measuring Performance and Consumer Satisfaction - Workshop Summary," Agency for Health Care Policy and Research, 4-6 June 1997.			
					AE( OC Tech
		T 3 0 Tall			
		·			RECEIVED OCT 3 0 2001 Technology Center 2100
Ped 7/21/05					
<ul> <li>EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.</li> </ul>					